Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 8/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19682479 | 0.78 | TRPV4 (0.70) | TRPV4 | |
| SCHEMBL23140910 | 0.78 | TRPV4 (1.00) | TRPV4SLC6A9 | |
| SCHEMBL29420303 | 0.78 | TRPV4 (1.00) | TRPV4SLC6A9 | |
| SCHEMBL1082080 | 0.75 | TRPV4 (0.61) | TRPV4PGREPAS1 | |
| SCHEMBL1080669 | 0.74 | TRPV4 (0.53) | TRPV4PGR | |
| SCHEMBL29825320 | 0.72 | MAP3K5 (0.42) | SLC6A9EPHX2GPR119 | |
| SCHEMBL23287020 | 0.72 | MAP3K5 (0.42) | SLC6A9EPHX2GPR119 | |
| SCHEMBL7765655 | 0.71 | TRPV4 (0.60) | TRPV4 | |
| SCHEMBL1020883 | 0.71 | TRPV4 (0.60) | TRPV4 | |
| SCHEMBL29948706 | 0.71 | TRPV4 (0.60) | TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790116-B | TRPV4 antagonists | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-11260049-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-03-01 | — | — | US | disclosed |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| EP-3515888-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| EP-3515888-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| WO-2018055526-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11260049-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885HRH3 933/4885ALK 1756/4885 |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885HRH3 933/4885ALK 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.